Christopher Lloyd
Director AstraZeneca
Seminars
Monday 8th June 2026
Unlocking Safe & Potent T-Cell Engagers by Applying Rational Design Principles to Maximise Efficacy & Minimise Toxicity
2:00 pm
- Tuning affinity, valency, and synapse engagement to optimise efficacy while maintaining safety
- Engineering CD8 T-cell selectivity to minimise CRS and ICANS without compromising therapeutic potency
- Presenting pre-clinical data on leading programs entering clinical trials
